Information Provided By:
Fly News Breaks for May 30, 2019
DGX, LH, MYGN
May 30, 2019 | 05:25 EDT
Piper Jaffray analyst William Quirk says Myriad Genetics (MYGN) management remains optimistic over incremental private payer coverage for GeneSight, but points out they are now guiding to finalized decisions by calendar year end, which is about three-to-six months later than his previous expectations. Quirk suspects the negotiations are taking longer than expected due to the study dynamics. The analyst, while appreciating investors' frustration over Myriad shares, believes the stock is trading "well below slower growing" LabCorp (LH) and Quest Diagnostics (DGX). A couple reimbursement wins will be enough to create a rally, Quirk tells investors in a research note. He keeps an Overweight rating on Myriad Genetics with a $45 price target.
News For MYGN;LH;DGX From the Last 2 Days
LH
Mar 28, 2024 | 16:23 EDT
Get caught up quickly on the top news and calls moving stocks with these five Top Five lists. 1... To see the rest of the story go to thefly.com. See Story Here
LH
Mar 28, 2024 | 08:03 EDT
Labcorp (LH) and OPKO Health (OPK) announce that they have entered into an agreement for Labcorp to acquire select assets of BioReference Health, a wholly owned subsidiary of OPKO Health. Through this transaction, Labcorp will acquire BioReference Health's laboratory testing businesses focused on clinical diagnostics and reproductive and women's health across the United States outside of New York and New Jersey. This transaction includes patient service centers and certain customer contracts and operating assets. BioReference Health will continue to offer oncology and urology diagnostic services nationwide, as well as maintain its full operations in New York and New Jersey. When complete, the transaction is expected to provide patients, physicians and customers with greater access to Labcorp's comprehensive, high-quality laboratory services, scientific expertise and expanded testing capabilities in key regions across the country. The assets that Labcorp will be acquiring currently generate approximately $100M in annual revenue. The purchase price for the transaction is $237.5M. The proposed acquisition meets Labcorp's strategic and financial criteria. The transaction is subject to customary closing conditions and applicable regulatory approvals, including under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended. The transaction is anticipated to close in the second half of 2024.